Prostatic Diseases and Male Voiding DysfunctionImpact of Minimally Invasive Benign Prostatic Hyperplasia Therapies on 30- and 90-Day Postoperative Office Encounters
Section snippets
Demographic Information
This study was approved by the Mayo Clinic Institutional Review Board. At our institution, 3 main surgical options (>30 cases/year) exist for BPH refractory to medical therapy: monopolar TURP, GL-PVP, and HoLEP. A total of 291 consecutive patients who underwent monopolar TURP (N = 199), HoLEP (N = 60), or GL-PVP (N = 32) for BPH at our institution between January 1, 2012 and December 31, 2014, were included in this retrospective study. All 6 surgeons performed TURP; however, a single surgeon
Demographic Information
A comparison of demographic, disease, and operative information between TURP patients, HoLEP/AP patients, and GL-PVP patients is shown in Table 1. Regarding demographic and disease information, characteristics were similar between the 3 surgery groups with the exception of preoperative PSA (P = .001), preoperative Qavg (P = .041), and preoperative PVR (P = .004). The differences in preoperative PSA between the 3 surgery groups are expected due to the nature of the surgeries, as larger glands
Discussion
The posthospital discharge period is subject to significant scrutiny, with aims to reduce rehospitalizations of paramount importance to the Centers of Medicare and Medicaid. Approximately 20% of the over 11 million Medicare beneficiaries reviewed from 2003 to 2004 were rehospitalized within 30 days of discharge.10 With respect to surgical diagnoses, 51.5% of patients who were discharged were rehospitalized or died within 1 year of discharge.10 Recognizing this flaw in healthcare delivery, the
Conclusion
Significant differences in postoperative encounters across 3 major BPH surgeries exist and transitioning to laser BPH therapies may place increased burden on clinic staff during both the 30-day and 90-day postoperative periods.
References (13)
- et al.
Techniques and long-term results of surgical procedures for BPH
Eur Urol
(2006) - et al.
Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies
J Urol
(2008) - et al.
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients
J Urol
(2008) - et al.
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement
Eur Urol
(2010) - et al.
The impact of unplanned postprocedure visits in the management of patients with urinary stones
Surgery
(2014) - et al.
Is transurethral resection of the prostate still justified?
BJU Int
(1999)
Cited by (0)
Previous Presentation: Southeast Section AUA Podium Presentation, March 18, 2016, Nashville, TN.
Financial Disclosure: The authors declare that they have no relevant financial interests.
Funding Support: Mayo Clinic Institutional Grant.